Clinical trials: Ticagrelor
Myocardial Infarction, Myocardial Fibrosis
Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction
This is a single-center, prospective, observational controlled cohort study designed to describe the role of WNT/B-catenin signaling and adenosine system after an acute myocardial infarction, correlating it with clinical markers…
- Conditions
- Myocardial Infarction, Myocardial Fibrosis, Myocardial Remodeling, Ventricular
- Trial name
- BETA-MI (NCT05122741)
- Testing
- P2Y12 Potent Inhibitor + Aspirin for STEMI patients, Clopidogrel + Aspirin for CCS patients
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Messina
Acute Coronary Syndrome, Myocardial Infarction
Future Optimal Research and Care Evaluation
Rationale: Acute coronary syndrome (ACS) is the leading cause of death worldwide. To improve cardiovascular care, research is needed.
- Trial name
- FORCE-ACS (NCT03823547)
- Where
- 4 sites in Netherlands
- Volunteers
- 99,999 people
- Sponsor
- J.M. ten Berg
Coronary Artery Disease
Reversal of the Anti-platelet Effects of Ticagrelor
The purpose of this study is to determine the proportion of untreated donor platelets required to fully reverse the platelet inhibitory effects of ticagrelor and aspirin in healthy persons and patients with coronary artery…
- Trial name
- REVERSAL (NCT02383771)
- Testing
- Ticagrelor, Aspirin + Ticagrelor, Control
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Chronic Coronary Syndrome
Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease
This is a prospective, multicenter, randomized, open-label trial with blinded endpoint adjudication (PROBE design), comparing one-month dual antiplatelet therapy (DAPT) with low-dose ticagrelor (60 mg BID) followed by ticagrelor…
- Trial name
- STELAR (NCT07080684)
- Testing
- Ticagrelor 60 mg, clopidogrel 75 mg
- Volunteers
- 1,000 people
- Sponsor
- University of Messina
Antiplatelet Therapy of Coronary Artery Bypass
A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting
This study is designed to demonstrate that the onset of the antiplatelet effect of 90mg bid dose ticagrelor is more rapid and greater than 75 mg qd dose clopidogrel in patients undergoing CABG surgery.
- Trial name
- ATCCC (NCT02330640)
- Testing
- ticagrelor, clopidogrel, asprin
- Where
- China
- Volunteers
- 137 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Peripheral Artery Disease (PAD)
Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR
To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have…
- Trial name
- TI-PAD EVR (NCT02227368)
- Testing
- Ticagrelor, Comparator
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus；, Stable Coronary Disease
A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage
The purpose of this study is to compare clopidogrel with ticagrelor which one has stronger anti-inflammation effect to protect against type 2 diabetes-induced vascular damage.
- Trial name
- NCT02214654
- Where
- 2 sites in China
- Volunteers
- 144 people
- Sponsor
- Tianjin Medical University
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
ST-segment Elevation Myocardial Infarction
Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction
Percutaneous coronary intervention(PCI) has become the first choice for STEMI patients.According to the current guidelines,dual antiplatelet therapy with a P2Y12 receptor inhibitor and aspirin ,and intravenous injection of…
- Trial name
- NCT02913469
- Testing
- Morphine, metoclopramide, saline
- Where
- China
- Volunteers
- 128 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Severe Aortic Valve Stenosis, Transcatheter Aortic Valve Implantation
Platelet Reactivity After TAVI: A Multicenter Pilot Study
A high platelet reactivity in patients with severe symptomatic Aortic Stenosis (AS) selected for TAVI (Transcatheter aortic valve implantation) procedure has been demonstrated previously, and the use of double antiaggregation…
- Conditions
- Severe Aortic Valve Stenosis, Transcatheter Aortic Valve Implantation, Transcatheter Aortic Valve Replacement
- Trial name
- REAC-TAVI (NCT02224066)
- Testing
- Ticagrelor 90 mg twice per day during three months following TAVI, Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI
- Where
- 7 sites in Spain
- Volunteers
- 65 people
- Sponsor
- Hospital de Meixoeiro
Coronary Artery Disease, Diabetes Mellitus. Type 2
Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)
Patients with type 2 diabetes mellitus (T2DM), have a high prevalence of suboptimal response to clopidogrel (up to 40%). This impaired response to antiplatelet drugs has been consistently associated with a higher risk of adverse…
- Trial name
- TICS-DM (NCT02457130)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 3 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Spanish Society of Cardiology
Peripheral Artery Disease
Post-operative Treatment of Diabetic Peripheral Arterial Disease Guided by Platelet Reactivity Unit
To compare the effect of PRU(platelet (P2Y12) reaction units)-guided treatment on the change in 1. time of initial leg pain and time of termination of exercise test by pain, evaluated on the graded stationary bicycle test, 2.
- Trial name
- NCT02762864
- Testing
- platelet (P2Y12) reaction units, ticagrelor, Comparator
- Volunteers
- 200 people
- Sponsor
- Chang Gung Memorial Hospital
Coronary Artery Disease, Stable Angina
The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery
In the POPular CABG study we investigate if the addition of ticagrelor, a drug that inhibits blood platelets from clotting, to treatment with aspirin will reduce the rate of saphenous vein graft occlusion as assessed with…
- Conditions
- Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
- Trial name
- POPular CABG (NCT02352402)
- Testing
- Ticagrelor
- Where
- 6 sites in Netherlands
- Volunteers
- 487 people
- Sponsor
- J.M. ten Berg
Unstable Angina Pectoris, Coronary Stent Implantation
Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation
The study is to evaluate efficacy and safety of low dose of ticagrelor therapy for Chinese unstable angina patients treated with non-urgent coronary stent implantation, to examine whether lower dose ticagrelor (45 mg twice-daily)…
- Trial name
- NCT03620760
- Testing
- Ticagrelor 90 mg, Ticagrelor 45 mg, Aspirin
- Where
- China
- Volunteers
- 2,036 people
- Sponsor
- Xiaofan Wu
Non-ST Elevation Acute Coronary Syndrome
Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.
The purpose of this study is to determine if ticagrelor is as effective as clopidogrel in rate of onset and degree of platelet inhibition for patients with non-ST elevation of acute coronary syndrome (NSTE-ACS) undergoing ad hoc…
- Trial name
- NSTE-ACS (NCT02052635)
- Testing
- ticagrelor, clopidogrel
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Renal Impairment
Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers
The main purpose of this study is to examine how AZD6140 affects patients with severe kidney disease compared to volunteers with normal kidneys. Subjects in the study will receive one dose of AZD6140.
- Trial name
- NCT00733265
- Testing
- AZD6140
- Where
- 4 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Disease
Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel
This study is designed to test the hypothesis that the onset of the antiplatelet effect 90mg-first-dose of ticagrelor will be more rapid and greater than 300mg-loading-dose of clopidogrel evaluated by P2Y12 reaction units…
- Trial name
- NCT02513004
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yongjian Wu
Atrial Fibrillation, Percutaneous Coronary Intervention
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT)…
- Trial name
- PIONEER AF-PCI (NCT01830543)
- Testing
- rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg
- Where
- 348 sites in United States, Argentina and 23 more
- Volunteers
- 2,124 people
- Sponsor
- Janssen Scientific Affairs, LLC
Coronary Artery Disease, Chronic Obstructive Pulmonary Disease
ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts
This is an investigator-initiated, prospective, single-centre, randomised, phase II, open-label study, testing the superiority of ticagrelor, as compared to clopidogrel, in modulating on-P2Y12 treatment platelet reactivity…
- Trial name
- NATHAN-NEVER (NCT02519608)
- Testing
- Aspirin 100 mg, Ticagrelor, Clopidogrel
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- University Hospital of Ferrara
Acute Coronary Syndrome
ARCANGELO (itAlian pRospective Study on CANGrELOr)
The Sponsor implemented a post-authorisation safety study (PASS), category 3, focused in Acute Coronary Syndrome, in order to collect information about the safety of cangrelor in the real clinical practice, evaluating the safety…
- Trial name
- ARCANGELO (NCT04471870)
- Where
- 30 sites in Italy
- Volunteers
- 1,005 people
- Sponsor
- Chiesi Farmaceutici S.p.A.